All In Biotech

Drug Trial Radar · NCT03621280

Open-label Treatment in Cushing's Syndrome

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Last checked: Nov 20, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

51

Actual

Start

Jan 7, 2019

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Cortendo ABIndustry
Sponsor type
Industry
First posted
Aug 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.

Conditions

  • Cushing Syndrome
  • Cushing Disease

Interventions

  • LevoketoconazoleDrug

    Levoketoconazole up to 1200 mg daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN)Time frame: From parent study Baseline to final study visit or up to a maximum of 3 years, whichever comes first.

Locations

30 sites in 11 countries. Site status is shown where the registry gives one.

  • The Center for Diabetes and Endocrine Care

    Fort Lauderdale, Florida

  • Emory University

    Atlanta, Georgia

  • Washington University School of Medicine

    St Louis, Missouri

  • University of New Mexico HSC - HSC Sponsored Projects Office

    Albuquerque, New Mexico

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Sveti Georgy University Hospital Clinic of Endocrinology and Metabolic Diseases

    Plovdiv, Bulgaria

  • Alexandovska University Hospital

    Sofia, Bulgaria

  • University Specialized Hospital for Active Treatment in Endocrinology

    Sofia, Bulgaria

  • APHM Hôpital de la Conception

    Marseille, France

  • General Hospital of Athens Evangelismos Department of Endocrinology and Diabete

    Athens, Greece

  • Hippokration General Hospital Endocrinology and Diabetes Department

    Thessaloniki, Greece

  • Semmelweis Egyetem II. Belgyógyászati Klinika

    Budapest, Hungary

  • Bnai Zion Medical Center Endocrinology Institute

    Haifa, Israel

  • Rabin Medical Center, Beilinson Campus

    Petah Tikva, Israel

  • Tel Aviv-Sourasky Medical Center Institute Endocrinology Metabolism & Hypertension

    Tel Aviv, Israel

  • Clinica Endocrinologia malattie del Metabolismo

    Ancona, Italy

  • AOU Policlinico G. Martino Sezione di Endocrinologia

    Messina, Italy

  • Via Sergio Pansini 5 Uni Naples FedericoII Dept of Molecular&Clinical Endocrinology&Oncology

    Naples, Italy

  • Policlinico Universitario Sant'Andrea

    Roma, Italy

  • University of Turin

    Turin, Italy

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • Instytut Centrum Zdrowia Matki Polki

    Lodz, Poland

  • Institutul National de Endocrinologie C.I. Parhon

    Cluj-Napoca, Romania

  • Spitalul Clinic Judetean de Urgenta Cluj-Napoca

    Cluj-Napoca, Romania

  • Spitalul Clinic Judetean Mures

    Târgu Mureş, Romania

  • Hospital Universidad De La Ribera

    Alzira, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.